about
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer CenterCurrent status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Troy Z Horvat
@ast
Troy Z Horvat
@en
Troy Z Horvat
@es
Troy Z Horvat
@fr
Troy Z Horvat
@nl
Troy Z Horvat
@sl
type
label
Troy Z Horvat
@ast
Troy Z Horvat
@en
Troy Z Horvat
@es
Troy Z Horvat
@fr
Troy Z Horvat
@nl
Troy Z Horvat
@sl
prefLabel
Troy Z Horvat
@ast
Troy Z Horvat
@en
Troy Z Horvat
@es
Troy Z Horvat
@fr
Troy Z Horvat
@nl
Troy Z Horvat
@sl
P106
P21
P31
P496
0000-0003-4756-8157